Research summary, original research, 2017

Dose-Decreasing Effect of the First Reversed Laser Beam Collimator for C-Arm Type Angiographic Equipment

Heo YC, Cho JH, Han DK. Journal of Korean medical science. 2017

Read the original paper

In plain language

In a bench test with 30 radiologists, a prototype laser device showing the X-ray field on a C-arm sharply cut fluoroscopy time and dose-area product during initial positioning. Staff dose was not measured, and the device was not tested in patients.

At a glance

Type of study
Original research, Phantom or simulation study
Who was studied
Other physicians, Phantom or simulation (no people)
Size
n = 30 radiologists
Summary based on
the full text

What it found

  • With a 2 mm positioning margin, the laser collimator reduced dose-area product (DAP) during positioning by 92.1%.

    Key figures: 70.4 ± 10.6 to 5.5 ± 4.7 mGycm2; -92.1%; P < 0.001

  • With a 2 mm margin, fluoroscopy time for positioning fell by 87%.

    Key figures: 18.5 ± 4.2 s to 2.4 ± 1.9 s; -87.0%

  • With a 10 mm margin, DAP fell by 97.6% and fluoroscopy time by 94.2%.

    Key figures: 58.6 ± 10.1 to 1.4 ± 0.5 mGycm2; 13.8 ± 3.9 s to 0.8 ± 0.4 s

  • Time needed for positioning also fell, by 40.2% (2 mm margin) and 71.8% (10 mm margin).

    Key figures: 40.2% and 71.8%

  • The authors identified practical problems with the prototype, including infection risk if it detaches, sensor error, and loss of focus when the detector moves.

Limits to keep in mind

This was a bench test of a prototype on a single Philips C-arm, using iron-ball targets rather than patients, so it covers only the positioning step. Staff dose was not measured (only DAP), and the stated percentage formula appears inconsistent.

How this summary was made

ORSIF prepared this summary with AI assistance from the full text of the paper. A program then checked that the passage supporting each finding appears word for word in that source. A person has not yet reviewed each summary, so read the original before relying on a number. ORSIF summarizes research and does not endorse any product or company. Report a problem with this summary.

Prepared November 3, 2026.